Ray Dalio Gilead Sciences, Inc. Transaction History

Bridgewater Associates, LP

$18.9 Billion
Q2 2024

A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 790,644 shares of GILD stock, worth $69.6 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares

790,644

Previous 1,011,768 21.86%

Holding current value

$69.6 Million

Previous $74.1 Million 26.81%

% of portfolio

0.29%

Previous 0.38%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $14 Million - $16.1 Million	-221,124 Reduced 21.86%	790,644 $54.2 Million
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $14.6 Million - $17.8 Million	203,849 Added 25.23%	1,011,768 $74.1 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $5.53 Million - $6.27 Million	75,408 Added 10.29%	807,919 $65.4 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $975,934 - $1.06 Million	-13,199 Reduced 1.77%	732,511 $54.9 Million
Q2 2023 Aug 11, 2023	BUY	$76.01 - $86.7 $18.9 Million - $21.6 Million	249,061 Added 50.15%	745,710 $57.5 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $16.9 Million - $19.2 Million	218,141 Added 78.32%	496,649 $41.2 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $522,989 - $750,832	-8,392 Reduced 2.93%	278,508 $23.9 Million
Q3 2022 Nov 10, 2022	SELL	$59.54 - $68.01 $17.8 Million - $20.3 Million	-298,584 Reduced 51.0%	286,900 $17.7 Million
Q2 2022 Aug 11, 2022	BUY	$57.72 - $65.01 $15.2 Million - $17.1 Million	263,412 Added 81.79%	585,484 $36.2 Million
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $16.2 Million - $20.2 Million	278,934 Added 646.61%	322,072 $19.1 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $96,087 - $109,060	-1,481 Reduced 3.32%	43,138 $3.13 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $5.56 Million - $6 Million	-82,091 Reduced 64.79%	44,619 $3.12 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $4.13 Million - $4.52 Million	65,118 Added 105.72%	126,710 $8.73 Million
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $659,520 - $752,512	10,992 Added 21.72%	61,592 $3.98 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $2.87 Million - $3.27 Million	50,600 New	50,600 $2.95 Million
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $7.56 Million - $8.32 Million	-122,718 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $1.93 Million - $2.13 Million	30,829 Added 33.55%	122,718 $7.78 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $2.03 Million - $2.27 Million	-32,739 Reduced 26.27%	91,889 $6.21 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $2.17 Million - $2.43 Million	-34,684 Reduced 21.77%	124,628 $8.1 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $7.55 Million - $9.85 Million	124,662 Added 359.77%	159,312 $9.97 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $1.26 Million - $1.39 Million	-17,666 Reduced 33.77%	34,650 $2.68 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $3.39 Million - $3.96 Million	52,316 New	52,316 $0

Others Institutions Holding GILD

# of Institutions

1,893

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.04M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account